Project Grant R03CA292552
Award Date
6/23/25
Completion Date
5/31/27
Dollars Obligated
$186K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug treatment for inhibiting cancer growth and metastasis, particularly for ovarian, lung, and colon cancers. The research aims to leverage tumor-associated hyperactive membrane-anchored serine proteases on the surface of malignant tumor cells to selectively deliver potent cytotoxins and enhance sensitivity...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $768,437 to the Sanford Burnham Prebys Medical Discovery Institute to conduct research aimed at identifying chemical compounds that inhibit the chromatin reader SGF29, which regulates the transcription of oncogenes in acute myeloid leukemia (AML). The research project will implement high-throughput screening assays developed by the institute to screen chemical libraries and identify...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $552,763 to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to conduct research on KAT6A as a novel druggable target for cancer treatment. The research aims to assess the therapeutic potential of newly developed KAT6 inhibitors (KAT6Is) as monotherapy and in combination with targeted therapy drugs in preclinical...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), provides $429,123 to Purdue University to develop improved inhibitors targeting the CBX8 chromodomain, which plays a role in driving cancer progression and chemotherapy resistance. The research aims to generate selective CBX8 inhibitors with enhanced cellular activity compared to current probes, in order to validate the selective inhibition of CBX8 as a viable...
This Project Grant award of $458,698.00 was provided by the National Cancer Institute (NCI) under the federal Cancer Biology Research program (CFDA 93.396). The award, effective March 10, 2025 through February 28, 2030, supports research to identify novel genes and mechanisms underlying therapy resistance and relapse in acute myeloid leukemia (AML). The research aims to functionally validate candidate genes from prior single-cell RNA sequencing and CRISPR screens in order to better understand...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to investigate the role of the DCAF15 E3 ligase in regulating the cohesin complex in acute myeloid leukemia (AML). The $483,760 award, effective from April 1, 2025 to March 31, 2030, aims to: (a) decipher the biological function of DCAF15 in myeloid development and leukemia in vivo, (b) investigate the role of cohesin acetylation in AML pathogenesis, and (c) develop small...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,881 to Duke University to develop novel immunotherapies using optimized tumor cell-penetrating antibodies. The primary objective is to translate these tumor cell-penetrating antibodies, which have demonstrated the ability to neutralize common oncogenic mutations like KRASG12D and control tumor growth, into the clinic. The research aims to elucidate the mechanisms...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) will provide $408,829 to the University of Pittsburgh to develop positive allosteric modulators that can enhance XCR1 signaling in cancer. The goal is to leverage this approach to improve anti-tumor immune responses, particularly by enhancing the function of a key subset of dendritic cells that are critical for initiating cytotoxic T cell responses against tumors. The award period runs from June...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $542,663 to The University of Texas MD Anderson Cancer Center to conduct preclinical research on using BRG1/BRM antagonists to treat acute myeloid leukemia (AML) with MLL rearrangement or mutant NPM1. The research aims to determine the efficacy of BRG1/BRM inhibitor and degrader compounds, evaluate combination regimens with these agents, and overcome resistance to menin inhibitors...